LLY financials
Eli Lilly and Company · end-of-day data as of Oct 16, 2026
Eli Lilly and Company
$1,257.03+5.3%
Buy · 31 analystsPT $1,313.62 +4.5%
LLY reported revenue of $22.97B for the quarter ended Jun 30, 2026 (Q2 FY2026), up 47.7% from a year earlier. It posted diluted EPS of $7.94, free cash flow of $7.76B and a net margin of 30.9%.
Valuation
- P/E42.2x
- P/E vs own+7.4%
- P/E vs sector+49.8%
- FCF yield+1.7%
- Market cap$1.18T
Quarterly results
Q2 FY2026: Revenue +47.7% year over year, free cash flow 33.8% of revenue, operating margin 54.2%.
RevenueFree cash flow
| Q2 FY2026 | Jun 30, 2026 | $22.97B | 7.94 | $7.76B | 85.8% | 54.2% | 30.9% |
| Q1 FY2026 | Mar 31, 2026 | $19.8B | 8.26 | $3.01B | 81.9% | 49.4% | 37.4% |
| Q4 FY2025 | Dec 31, 2025 | $19.29B | 7.39 | $678M | 82.5% | 46.6% | 34.4% |
| Q3 FY2025 | Sep 30, 2025 | $17.6B | 6.21 | $8.61B | 82.9% | 47.6% | 31.7% |
| Q2 FY2025 | Jun 30, 2025 | $15.56B | 6.29 | $1.28B | 84.3% | 45.1% | 36.4% |
| Q1 FY2025 | Mar 31, 2025 | $12.73B | 3.06 | -$1.6B | 82.5% | 41.7% | 21.7% |
| Q4 FY2024 | Dec 31, 2024 | $13.53B | 4.88 | $727M | 82.2% | 42.0% | 32.6% |
| Q3 FY2024 | Sep 30, 2024 | $11.44B | 1.07 | -$459M | 81.0% | 38.8% | 8.5% |
| Q2 FY2024 | Jun 30, 2024 | $11.3B | 3.28 | $63.4M | 80.8% | 39.1% | 26.3% |
| Q1 FY2024 | Mar 31, 2024 | $8.77B | 2.48 | $180M | 80.9% | 31.2% | 25.6% |
| Q4 FY2023 | Dec 31, 2023 | $9.35B | 2.42 | -$1.96B | 80.9% | 34.1% | 23.4% |
| Q3 FY2023 | Sep 30, 2023 | $9.5B | -0.06 | -$1.81B | 80.4% | 37.3% | -0.6% |